Glenmark gets USFDA nod for Icatibant injection single-dose prefilled syringe

This marks Glenmark’s first synthetic decapeptide injectable approval

67
FDA

Last Updated on May 26, 2021 by The Health Master

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (USFDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, the generic version of Firazyr Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, of Shire Human Genetic Therapies.

This marks Glenmark’s first synthetic decapeptide injectable approval and will be manufactured in their North American manufacturing facility based in Monroe, North Carolina.

Medicine Injection drug vaccine
Picture: Pixabay

According to IQVIA sales data for the 12 month period ending March 2021, the Firazyr Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe market achieved annual sales of approximately $223.4 million*.

Glenmark’s current portfolio consists of 172 products authorised for distribution in the US marketplace and 44 ANDA’s pending approval with the US FDA.


Other approvals:

NATCO Pharma gets USFDA nod for Everolimus tablets

Natco Pharma gets USFDA nod for Lenalidomide capsules

Unichem Labs gets USFDA approval for Amitriptyline HCL Tablets

Alembic gets USFDA Final nod for Lurasidone HCL Tablets

Alembic gets USFDA nod for depression treatment drug

Caplin gets USFDA nod for Neostigmine Methylsulfate Injection


Also read:

Latest Notifications: Hospital – RMI (Recognized Medical Institution)

Paediatric trials of Covaxin are likely to start from June 1

Pharma Cos behind dropping plasma therapy: Experts

Bharat Parenterals gets DCGI nod for Favipiravir oral suspension

NATCO Pharma gets USFDA nod for Everolimus tablets

Natco Pharma gets USFDA nod for Lenalidomide capsules

Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner